Rafael Casiano Cuevas on LinkedIn: Unlock the three keys to drug discovery success. Learn how Labcorp’s… (2024)

hom*ologous recombination deficiency (HRD) testing helps guide personalized PARP inhibitor therapy for patients living with ovarian cancer. Tune in to Labcorp Perspectives to hear from Dr. Rebecca Previs and Dr. Alison Roos on how expanded HRD testing can transform precision medicine and improve outcomes for ovarian cancer patients.Check out the latest episode to learn more about the future of precision medicine: https://lnkd.in/enJcHX5i#PrecisionOncology#PersonalizedMedicine #CancerResearch #GynOnc

Come visit us in Boston at the World Clinical Biomarkers & CDx Summit to find out how we can help accelerate your biomarker-driven oncology therapeutic development at every stage. Schedule a meeting in advance and explore our solutions: https://lnkd.in/eWH_nPW5#WorldCDx

Labcorp is a proud sponsor of this year’s World CB & CDx Summit in Boston, MA. Please join us for a special presentation on Wednesday, Sept. 4 at 5:00 p.m. ET where Dr. Mark Roberts, head of Precision Medicine, will talk about “Advancing Precision Medicine Globally: From Gene Therapy to HLA CDx Commercialization." Learn more: https://lnkd.in/eWH_nPW5#WorldCDx

Labcorp helped accelerate a biotech sponsor's novel CAR T-cell cancer therapies by 6-12 months using deep cell therapy expertise. Learn how our integrated preclinical, clinical and lab services resulted in an optimized preclinical program, data-driven trials and seamless COVID-19 pivots: https://lnkd.in/edG_Pdve#CellandGeneTherapy #CellTherapy #CARTCell #ClinicalDevelopment

1

Join Drs. Kyle C. Strickland and Rebecca A. Previs from Labcorp Oncology’s medical affairs team to learn about tissue stewardship from a pathologist’s and oncologist’s perspective. They will review data from advanced non-small cell lung cancer (NSCLC) while sharing best practices to optimize tissue utilization and help ensure patients with advanced NSCLC receive all recommended biomarker testing. Register here: https://lnkd.in/ezK3NMmU

Due to their highly nuanced chemistry, antibody-drug conjugates (ADCs) require an experienced bioanalytical laboratory to progress through clinical trials. With extensive bioanalytical capabilities, Labcorp has supported nearly half of all approved ADCs currently on the market, making us an ideal collaborator to advance your ADC throughout the drug development journey. Learn how our bioanalytical services enable ADC developers like you to bring these innovative treatments to market: https://lnkd.in/ebqRjEQz

Join Us at the Next Generation Dx Summit in Washington D.C.! We’re excited to present groundbreaking data on our newly FDA-authorized liquid biopsy assay, PGDx elio™ plasma focus Dx.Dr. Kenneth Valkenburg, PhD, Director of Research & Development at Labcorp Oncology will discuss “Enabling Access to Genomic Profiling through Decentralized Liquid Biopsy Solution, PGDx elio Plasma Focus Dx”For more information on PGDx elio plasma focus Dx, please visit: https://lnkd.in/gk4VwceN gen dx&utm_term=&utm_marketing_tactic=aw

At Labcorp Oncology, we use the OmniSeq® INSIGHT assay to perform comprehensive genomic and immune profiling on patients with solid tumors to identify actionable biomarkers for a more personal approach. Want to know how it works? Learn more: https://lnkd.in/gXrMKYpT

2

Labcorp will be participating in the 9th Annual CAR-TCR Summit this September. In a special summit presentation, Leanne Flye-Blakemore, associate director of scientific operations for flow cytometry, will discuss the future of flow cytometry in adoptive cell therapies, highlighting key cellular biomarkers, accelerated immune monitoring and the importance of sample type considerations. She will also cover standardization for consistent global data in long-term studies.Don’t miss this insightful session: https://lnkd.in/gnctbx-5